|
||
 |
CHINA HEALTH SCIENCES NEWSLETTER
Vol. 4 , No. 19 - December 10, 2003
TOPICS THIS ISSUE:
- Chongqing Develops Vaccine for Gastric Diseases
- Top Chinese drug maker joins Singapore start-up in TCM venture
- Chinese Research Center to Treat Chronic Bedwetting Syndrome
- Vion Receives Initial Payment from Beijing Pason License Agreement
|
LEHMAN, LEE & XU China Law Teleseminars |
Chongqing Develops Vaccine for Gastric Diseases
On November 18, 2003, The Third Military Medical University (TTMMU) unveiled one kind of vaccine for gastric diseases in its genetic engineering projects, which was researched and developed by TTMMU. At the same time, it is also the world's first kind of vaccine for gastric diseases. Its name is Helicobacter Pylori Vaccine (HPV). In addition, World Health Organization (WHO) has determined that HPV is one of its key projects in the coming 10years.
Through more than 10 years efforts, TTMMU eventually develops the first oral HPV around the globe. The move has always been sponsored by the National 863 Plans, and key technological projects of China's 9th Five-year-plan.
Animal experiments reveal that HPV's immune effect reaches over 90%, and oral HPV will function for 10 to 15 years. In May 2003, State Food and Drug Administration of the People's Republic of China (SFDA) approved that TTMMU began clinic experiments. If successfully, TTMMU will make HPV in 2005.
At present, in order to push industrialization of the global first vaccine for gastric diseases, TTMMU has founded a new company, Chongqing Kangwei Bio-technology Co., Ltd., with Yueyang Xingchang Petrochemical Co., Ltd. (YXP) and Chongqing Yangchun Bio-technology Co., Ltd.
(Source: Comtex News Network)
|
Top Chinese drug maker joins Singapore start-up in TCM venture
One is a giant Chinese pharmaceutical manufacturer, the other just a small two-year-old Singapore start-up engaged in the research and development of Traditional Chinese Medicine (TCM) products. But they are coming together in a joint-venture that will see the Shanghai-listed North China Pharmaceutical inject S$6 million into a 40 percent stake in Henan Han's TCM Biotechnology of Singapore.
The joint-venture is already making plans to set up an R&D and manufacturing base here, and list on the Singapore Exchange in two years' time. Henan Han TCM Biotechnology's expertise is in the research and development of traditional Chinese medicine products.
11 TCM products the start-up has developed, three of which have been approved by the Health Sciences Authority for distribution. It even has products that it claims are effective against the SARS virus and will be putting them through clinical trials. The firm's current intellectual property rights are valued at S$15 million. These products are developed by company chairman, Dr Han Zhen Shan, a famous TCM physician from China's Henan province.
Dr Han is regularly consulted on health matters by top-ranking Chinese officials, including ministers. Together with Singapore partners, Dr Han set up Henan Han TCM to conduct his R&D here, in order to take advantage of the Singapore government's many incentives like tax breaks and research grants.
"The Chinese market is the biggest potential market that we are targetting. That is why the venture with North China Pharmaceutical Company is a good synergy for us to tap the market in China," said Christopher Sim, chief executive of Henen Han's TCM Biotechnology. "Our partners have a wide distribution network. Actually they supply to 10,000 hospitals and 50,000 clinics in China," he said.
(Source: MCN International)
Chinese Research Center to Treat Chronic Bedwetting Syndrome
American Oriental Bioengineering, Inc., a leading Chinese biotechnology company, today announced it will launch a research center in China focused on helping treat patients suffering from enuresis or chronic bedwetting syndrome through the Company's flagship medical product, Cease- Enuresis Soft Gel.
Shujun Liu, Chief Executive Officer of American Oriental Bioengineering, commented, that the availability of treatment options for enuresis, or bedwetting, is currently under-whelming, despite the fact that the disease plagues so many children and adults. He believe that this disease represents another attractive business opportunity and substantial market potentials for the Cease-Enuresis Soft Gel, the Company's flagship product for curing bedwetting, since the needs of this large, recurring market are presently underserved.
There are two types of enuresis, primary and secondary. In primary enuresis, control of the bladder has never been attained. In secondary enuresis, bladder control once present for some reason is lost. Onset of bedwetting after the child has been dry for at least 6 months. Various causes for enuresis have been cited, including stress, repressed anger and the potential for the disease to be inherited. Many of those inflicted ultimately fail to seek out treatment because of the lack of knowledge and treatment for such a problem.
(Source: PR Newswire Association)
|
Please contact us for Business development
and Pharmaceutical licensing opportunities |
is the agent of 
in China. Pharmalicensing is a web-based company that provides highly
efficient marketing tools for companies in the pharmaceutical and
biotech industries. Pharmalicensing aims to increase awareness of
your company through their large business development audience and
to proactively match and forward to your company potential out-licensing,
in-licensing- and cooperation partners. |
 |
 |
Vion Receives Initial Payment from Beijing Pason License Agreement
Vion Pharmaceuticals, Inc. announced recently that the Company had received the initial payment of US$500,000 from Beijing Pason Pharmaceuticals, Inc. ("Pason") associated with the recently signed license agreement to develop Triapine(R). Under this agreement, Pason obtained exclusive rights to develop, manufacture and market Triapine(R) for anticancer and antiviral uses in the mainland of the People's Republic of China, Taiwan, Hong Kong and Macao (the "Territory").
Dr. Sen Liu, Chief Executive of Pason, said, "Our plan is to initiate clinical trials of Triapine(R) for the treatment of cancer in the first half of 2004." He added, "Also in 2004, Pason plans to extend preclinical testing of Triapine(R) for antiviral uses, and to conduct additional preclinical studies of a Triapine(R) oral formulation, which demonstrated excellent absorption in a preliminary clinical study conducted by Vion. An oral formulation will significantly expand the development opportunities for Triapine(R) in both cancer and antiviral applications."
Alan Kessman, Chief Executive Officer of Vion, said, "The license agreement with Pason will broaden the development of Triapine(R) by exploring new cancer and non-cancer indications, as well as add to the evaluation of the oral formulation. We are pleased with the progress and aggressive timetable set forth by Pason to move Triapine(R) forward into human trials in the Territory."
Vion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel agents for the treatment of cancer. Beijing Pason Pharmaceuticals, Inc. ("Pason") is a pharmaceutical company focused on the development of anti-cancer and anti-HBV drugs.
(Source: PR Newswire Association)
Lehman Lee & Xu
A Licensed Chinese Law Partnership
|
Beijing Office
|
Shanghai Office
|
|
6th floor, Dongwai Diplomatic Office Building |
Suite 1310, Kerry Centre |
|
 |
The China Health Sciences Newsletter is intended to be used for news purposes only. It should not be taken as comprehensive legal advice, and Lehman, Lee & Xu will not be held responsible for any such reliance on its contents.
|
|
|
Internet Explorer users,
please click here: |
|
Netscape users, please send email to: hs@lehmanlaw.com
|
